PA-BOOMI
15.4.2024 15:01:27 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced findings from its Boomi Discovery Report, commissioned by 451 Research.1 The report, based on perspectives from 650 business and IT leaders across a broad range of industries, outlines how enterprises are using Generative AI (GenAI) to integrate systems and automate processes, and how this has helped their business operations as a result.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415795607/en/
Boomi Discovery Report Reveals More Than Half of Enterprises Invest in GenAI for Integration and Automation (Graphic: Business Wire)
Every business is grappling with growing digital fragmentation – from application sprawl and disconnect between departments, to rising costs and skills shortages. GenAI delivers the promise of more efficient and cost-effective operations and improved customer and employee experiences, but only for businesses that embrace it.
According to the Boomi Discovery Report, organizations are seeing GenAI’s immediate impact on integration. More than half of respondents (55%) said GenAI was very important for integrating data, applications, and processes. Moreover, the global drivers of AI adoption included increased productivity (which 44% of executives cited), increased sales and revenue growth (40%), and improved customer experience (39%).
However, respondents acknowledged the complexity that’s often associated with integration. Many times, integrating data and systems can bring challenges that prompt security and privacy concerns (42%), data quality and availability challenges (42%), and model training, accuracy, and reliability (31%). According to the report, 90% of respondents agree that GenAI has the potential to improve the speed and quality of the development and automation of data, application, and process integrations.
“The ability to seamlessly integrate and automate business processes has long been a top priority for many enterprises,” said Steve Lucas, CEO at Boomi. “As organizations scale and continue to navigate unforeseen business challenges, it will become more difficult to keep track of all the data, technology, and processes necessary to achieve business goals. Generative AI can be a powerful tool for today’s enterprises, streamlining valuable integration and automation practices and freeing IT teams to focus on innovation. Finding ways to leverage GenAI effectively is the next business prerogative. Boomi is not only helping get businesses ready for it, but also leading the GenAI charge in the integration and automation space."
Additional key findings from the report include:
- IT leaders have more trust in GenAI than business leaders: IT CxOs have a higher rate of trust – 82% either “completely” or “somewhat” trust the output of GenAI, versus 63% of business CxOs.
- Accuracy and consistency are major factors driving trust in GenAI: More than half of business leaders (57%) cited accuracy and quality of AI outputs as a factor in their trust of AI. Just under half (48%) cited consistency and reliability as an AI trust factor.
- Enterprise execs see tremendous value in GenAI: Leaders cited improved process accuracy and consistency (38%), cost reduction (38%), innovation and creativity (34%), streamlined operations (31%), optimized resources (28%), and enablement of competitive advantage (27%) as top potential benefits for leveraging GenAI.
- GenAI has widespread value for integrations: All respondents believe that virtually any type of integration would benefit from GenAI-assisted integration platforms.
“Integration and automation are the foundation upon which enterprises build business agility,” said Matt McLarty, CTO at Boomi. “However, integrating and automating systems isn’t always easy. This is why it pays off to have a unified approach for both. With a unified platform, powered by AI technology, enterprises can gain the advantages of comprehensive integration and automation while mitigating unwanted complexity.”
For more information on the 2024 Boomi Discovery Report, click here.
Additional Resources
- Learn more about the Boomi platform
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
Methodology
The findings presented in this report draw on a survey fielded in North America and Europe in Q4 2023. The survey targeted 650 business and IT decision-makers/influencers in companies ranging in size from under 100 to over 25,000 employees, and $2 million to over $10 billion in annual revenue. The study prioritized respondents with intimate knowledge of automation and integration technology across a broad range of diverse industries asking them about their perception of, and propensity to use, AI technologies of various types, but more specifically about their use of GenAI. The job descriptions of respondents were a mix of executives ranging from Analyst/Manager grade to C-level Executives. This report also draws on contextual knowledge of additional research conducted by S&P Global Market Intelligence.
|
|
1Source: The Impact of AI on Enterprise Integration and Automation, 451 Research, a part of S&P Global Market Intelligence and Boomi, 2024. All Rights Reserved |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415795607/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
